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ttp://dx.doi.org/10.1016/j.ajpath.2014.07.010Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs after
dental-related interventions in patients undergoing treatment with bisphosphonates or denosumab, the
neutralizing human antiereceptor activator of NF-kB ligand (RANKL) antibody (Ab). The cause of ONJ by
these drugs has been speculated to their direct effects on osteoclasts. However, the extent to which
osteoclasts contribute to ONJ pathogenesis remains controversial. Herein, by using a tooth-extraction
mouse model with i.v. administration of mouse anti-RANKL Ab or the bisphosphonate zoledronate (ZOL),
we show that unresorbed bone due to impaired formation or suppressed functions of osteoclasts,
respectively, is associated with ONJ development. After tooth extraction, ONJ-like lesions developed 50%
in the anti-RANKL Ab-treated mice and 30% in the ZOL-treated mice. Nonviable and unresorbed bone was
found more in anti-RANKL Ab-treated mice compared with mice receiving ZOL. All mice receiving anti-
RANKL Ab had an undetectable tartrate-resistant acid phosphatase (TRAP) level in the serum and no
TRAP-positive osteoclasts at the extracted sockets, whereas ZOL-treated mice had a decreased TRAP level
without altering the numbers of TRAP-positive osteoclasts. Interestingly, the absence of newly formed
woven bone in the extracted sockets was evident in ONJ-like lesions from both anti-RANKL Ab- and ZOL-
treated mice. Our study suggests that the lack of osteoclasts’ bone-resorptive functions by these drugs
and suppression of woven bone formation after dental trauma may be associated with ONJ development.
(Am J Pathol 2014, 184: 3084e3093; http://dx.doi.org/10.1016/j.ajpath.2014.07.010)Supported in part by National Institute of Dental and Craniofacial Research/
NIH grants R03DE021114 and R01DE023348 (R.H.K.), Dean’s Faculty
Research Seed grant (R.H.K.), and Chancellor’s grant (N.-H.P.).
Disclosures: None declared.Bisphosphonates (BPs) and denosumab (Dmab) are anti-
resorptive drugs that are clinically being used to treat bone-
related diseases, such as osteoporosis or cancers with bone
metastasis. Users of these drugs are known to be at higher riskstigative Pathology.
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Role of Osteoclasts in ONJof developing osteonecrosis of the jaw (ONJ), speciﬁcally in
the oral cavity after dental interventions, which is clinically
deﬁned as exposed necrotic bone and unclosed overlaying oral
mucosa for at least 8 weeks.1 In particular, ONJ incidence in
patients with cancer (eg, breast, prostate, ormultiplemyeloma)
receiving i.v. BPs is reported to range from 2% to 15%,2
although ONJ development in osteoporotic patients still re-
mains controversial. Two recent randomized clinical trials
comparing the bisphosphonate zoledronate (ZOL)- with
Dmab-treated patients with cancer revealed that the incidences
of BP- and Dmab-related ONJ (BRONJ and DRONJ, respec-
tively) were comparable in these two groups,3,4 suggesting
that ONJ induced by both drugs is a considerable clinical
complication that compromises patients’ quality of life.
Several animal models have been established for BRONJ
to examine the ONJ pathophysiological characteristics by
BPs,5e8 and these studies unequivocally showed that oste-
oclasts (bone-resorbing cells that are critically important for
bone remodeling9) are the key mediators in causing ONJ.
Nonetheless, direct evidence of osteoclasts’ involvement
and the extent to which osteoclasts contribute to ONJ
pathogenesis remains elusive, presumably due to the pleo-
tropic effects of BPs. Indeed, it remains unclear whether
ONJ development by BPs is associated directly with their
inhibitory effects on osteoclasts’ bone-resorptive functions
or indirectly with aberrant osteoclasts’ behaviors after BP
uptake (eg, secretion of cytokines to the surrounding envi-
ronment). Current literature also remains inconclusive with
respect to the presence, numbers, and location of mature
osteoclasts.7,8,10 Cytotoxic effects of BPs on cells other than
osteoclasts (eg, endothelial cells or oral mucosal cells)2
further complicate roles of osteoclasts in the ONJ patho-
physiological characteristics in the BRONJ models.
AlthoughBPs are smallmolecules thatmay affect cells other
than osteoclasts, Dmab is a fully human monoclonal antibody
(Ab) that is highly speciﬁc to osteoclasts by targeting receptor
activator ofNF-kB ligand (RANKL),which plays a central role
in osteoclastogenesis affecting the formation, function, and
survival of osteoclasts.11 Clinically, Dmab has less severe
adverse effects, such as gastrointestinal tract ulceration or
kidney dysfunction, when compared with BPs.9 In the human
RANKL knock-inmicemodel, it was demonstrated that Dmab
treatment resulted in >95% reduction in serum tartrate-
resistant acid phosphatase (TRAP)-5b in as early as 7 days,12
indicating that Dmab signiﬁcantly inhibits the formation of
mature osteoclasts in vivo. Because Dmab also induces ONJ in
the absence of osteoclast formation without signiﬁcant cyto-
toxic effects, it is possible that ONJ development is primarily
associated with structural defects (eg, unresorbed bone sur-
faces) as a result of impaired osteoclasts’ functions or formation
by BPs or Dmab, respectively, leading to incomplete healing
after dental-related traumas, such as tooth extraction or local
inﬂammation.
To examine experimentally whether osteoclasts are the
required mediators in ONJ development, we speciﬁcally
inhibited osteoclastogenesis in vivo by using theThe American Journal of Pathology - ajp.amjpathol.orgneutralizing mouse anti-RANKL Ab and established the
DRONJ mouse model. We compared this DRONJ mouse
model with that of BRONJ and examined the involvement




Eight-week-old female C57BL/6 mice were purchased from
the Jackson Laboratory (Bar Harbor, ME) and kept in a
pathogen-free vivarium in the University of CaliforniaeLos
Angeles, Division of Laboratory Animal Medicine. All ex-
periments were performed according to the approved insti-
tutional guidelines from the Chancellor’s Animal Research
Committee (number 2011-062).
Mouse Model for BRONJ and DRONJ
For the DRONJ mouse model, two groups of female
C57BL/6mice (nZ 20 per group) were i.v. injected with 250
mg of anti-mouse RANKL monoclonal Ab (IK22-5)13 or
control rat IgG (Sigma-Aldrich, St. Louis, MO) in phosphate-
buffered saline (PBS) through the tail veins biweekly for 4
weeks. For the BRONJ mouse model, 125 mg/kg ZOL
(Zometa; Novartis Oncology, East Hanover, NJ) or vehicle
(Veh) solution (0.9% NaCl saline) was also i.v. administered
biweekly for 4 weeks (n Z 10 per group). Under general
anesthesia using ketamine/xylazine (100 and 5 mg/kg,
respectively), the maxillary ﬁrst molar was atraumatically
extracted 1 week after the initial injection. Three weeks after
the tooth extraction, the mice were sacriﬁced to harvest
blood. The maxilla and femur were also harvested from each
mouse and ﬁxed with 4% paraformaldehyde in PBS, pH 7.4,
at 4C overnight and stored in 70% ethanol solution. After
micro-computed tomography (mCT) scanning, these tissues
were decalciﬁed with 5% EDTA and 4% sucrose in PBS, pH
7.4. Decalciﬁcation continued for 2 to 3 weeks at 4C, and the
decalciﬁcation solution was changed daily. Tissue samples
were sent to the UCLA Translational Procurement Core
Laboratory and processed for parafﬁn embedding.
mCT Scan and Three-Dimensional Volumetric Analysis
Areas of interest on the maxilla and femur were subjected to
mCT scanning (Scanco mCT 40; Scanco Medical, Brütti-
sellen, Switzerland) using a voxel size of 20 mm3 and a
0.5-mm aluminum ﬁlter. Image analysis was performed
using mCT software version 6.1 (Scanco Medical). mCT
scans were performed at 55 kVp and 145 mA with an
integration time of 200 milliseconds using a cylindrical
tube (ﬁeld of view/diameter, 20.48 mm). Resolution
was set to medium (1024  1024  148 pixels). Two-
dimensional slices from each maxilla or femur were com-
bined using the mCT software version 6.1 (Scanco Medical)3085
Figure 1 Establishment of the osteonecrosis of
the jaw (ONJ) mouse models for DRONJ and
BRONJ. The schematic timelines for the DRONJ (A)
and BRONJ (B) models. C and D: Three weeks after
tooth extraction, maxillae were harvested, clinical
presentations were imaged (left panels), and mCT
scans of the maxillae were taken. The occlusal
views (middle panels) and the angled views (right
panels) are shown. The black arrows resorbed
alveolar ridges (C and D); black arrowheads (C
and D), new bone in socket; red arrows (C and D),
unresorbed alveolar ridges; red arrowheads (C and
D), no bone in socket; white arrowheads (C and
D), open wound.
Williams et alto form a three-dimensional reconstruction. Reconstructions
were manipulated so that the viewing angles could provide an
accurate representation of bone resorption after 3 weeks of
healing. Several parameters were determined quantitatively
using the Scanco software on three-dimensional re-
constructions of the collected femurs. Bone volume (BV;
mm3) and the total volume (TV; mm3) were measured to
obtain percentage bone volume (BV/TV). The trabecular
number (1/mm), trabecular thickness (mm), and trabecular
separation (Tb.Sp; mm) were also determined on reconstruc-
tion of each femur. Newly formed bone in the tooth-extracted
sites was quantiﬁed by selecting a volume containing the
mesial, distal buccal, and distal lingual roots. Mean volumes
are displayed as percentage BV/TV. The scanning and ana-
lyses of data abide by the published guidelines for assessing
bone microstructure in rodents.14
Histochemical Staining
TRAP staining was performed as described previously.15
Brieﬂy, EDTA-decalciﬁed tissue sections were deparafﬁ-
nized at 60C for 30 minutes. The slides were rehydrated








IgG (n Z 20) 18 (90) 2 (10)
a-RANKL Ab (n Z 20) 8 (40) 12 (60)
Veh (n Z 10) 7 (70) 3 (30)
ZOL (n Z 10) 6 (60) 4 (40)
Ab, antibody; RANKL, receptor activator of NF-kB ligand; Veh, vehicle; ZOL, zo
3086solution, according to manufacturer’s protocol (Acid Phos-
phatase Kit; Sigma-Aldrich, Inc., St. Louis, MO). The slides
were counterstained with hematoxylin solution and mounted
with medium (Permount; Fisher Scientiﬁc, Tustin, CA).
Histomorphometric Analysis
To evaluate the degree of ONJ-like lesions, we quantiﬁed the
amounts of empty lacunae and necrotic bone. Three samples
from control IgG-treated group and anti-RANKLAbetreated
group, with or without ONJ-like lesions, were randomly
selected, and four sections (1, 6, 11, and 16) per sample were
stained with hematoxylin and eosin (H&E). For each section
that contains an area of interest covering ﬁrst molar extracted
sites horizontally from the buccal plates toward the palatal
suture (approximately 1.4 mm) and vertically from the tip of
the extracted site to the bottom of the palatal bone (approxi-
mately 0.8 mm), the digital images of each section were ob-
tained using the microscope (model DP72; Olympus, Center
Valley, PA) at 100 magniﬁcation. The percentage of
necrotic bonewas deﬁned as an area that contains ﬁve ormore
empty lacunae per 1 mm2 divided by total bone areas. The
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Figure 2 Anti-RANKL Ab treatment induces osteonecrosis of the jaw (ONJ)-like lesions. H&E-stained tissue at tooth-extracted sites from mice i.v.
administered with IgG (A) as well as anti-RANKL Ab that induced (B) or did not induce (C) ONJ-like lesions. The numbers of empty lacunae per mm2 (D) and the
percentage of necrotic bones (E) were quantiﬁed. *P < 0.05, **P < 0.01. Scale bars: 100 mm (AeC). The black arrow (A) indicates resorbed alveolar ridge;
red arrows (B and C), unresorbed ridge; white (A) and red (C) arrowheads, margin between existing lamellar bone and newly formed woven bone. CT,
connective tissue; ET, epithelial tissue; LB, lamellar bone; PEH, pseudoepitheliomatous hyperplasia; WB, woven bone.
Role of Osteoclasts in ONJarea (#/mm2). The total bone surface area wasmeasured using
ImageJ software version 1.48 (NIH, Bethesda, MD).
Blood Chemistry
Serum samples collected from each mouse were stored in
20C and thawed once. The presence of TRAP-5b was
detected by sandwich ELISA using the MouseTRAP Kit
(Immunodiagnostic Systems, Fountain Hills, AZ). The pro-
cedure was performed according to the manufacturer’s pro-
tocol, and serum samples were assayed in triplicate. Serum
levels of alkaline phosphatase (ALP) were determined by theThe American Journal of Pathology - ajp.amjpathol.orgUCLA Division of Laboratory Animal Medicine Diagnostic
Laboratory.
Statistical Analysis
The measures of key outcomes (eg, percentage bone volume,
trabecular number, trabecular thickness, TRAP-5b, ALP,
empty lacunae, or necrotic percentages) were expressed as
meansSD.A two-group t-testwas used to compare themeans
of outcomes between the groups. A two-way table c2 test was
used to evaluate epithelialwoundclosure 3weeks after the tooth
extraction. P < 0.05 was considered statistically signiﬁcant.3087
Figure 3 Zoledronate (ZOL) treatment induces osteonecrosis of the jaw (ONJ)-like lesions. H&E-stained tissue at tooth-extracted sites from mice i.v.
administered with Veh (A) or ZOL that induced (B) or did not induce (C) ONJ-like lesions. Quantiﬁcation of the numbers of empty lacunae per mm2 (D) and the
percentage of necrotic bones (E). *P < 0.05. Scale bars: 100 mm (AeC). The black arrow (A) indicates the resorbed alveolar ridge; red arrows (B and C),
unresorbed ridge; white (A) and red (C) arrowheads, margin between existing lamellar bone and newly formed woven bone CT, connective tissue; ET,
epithelial tissue; LB, lamellar bone; PEH, pseudoepitheliomatous hyperplasia; WB, woven bone.
Williams et alResults
Anti-RANKL Ab or ZOL Treatment Induces ONJ-Like
Lesions in Mice
To directly evaluate the involvement of osteoclasts in ONJ
development, we used anti-RANKL Ab or ZOL in a
tooth extraction mouse model. Biweekly administration of
anti-RANKLAb and ZOL for 4 weeks increased bone mass, as
demonstrated by bone morphometric analysis (Supplemental
Figure S1), conﬁrming systemic effects of anti-RANKL Ab3088and ZOL. To induce ONJ, the maxillary ﬁrst molar was
extracted 1 week after initial anti-RANKL Ab treatment. Anti-
RANKL Ab was continually administered for an additional 3
weeks, after which the mice were sacriﬁced (Figure 1A).
Typical wound closure after an atraumatic tooth extraction
usually occurs within 3 weeks (Supplemental Figure S2).
Clinical presentation at the extracted sites after 3 weeks showed
complete epithelial closure in 90% (18 of 20) mice treated with
control IgG (Figure 1C and Table 1). In contrast, only 40% (8 of
20) of the mice in the anti-RANKL Ab-treated group had
complete epithelial closure (Figure 1C and Table 1), indicatingajp.amjpathol.org - The American Journal of Pathology
Figure 4 Mature osteoclasts are absent in anti-RANKL Ab-treated, but not in zoledronate (ZOL)-treated, mice. Three weeks after initial i.v. administration
and 2 weeks after tooth extraction, the maxillae were harvested and EDTA decalciﬁed. A: TRAP staining was performed at the tooth-extracted sites from mice
i.v. administered with IgG or anti-RANKL Ab that induced or did not induce ONJ-like lesions. B: Quantiﬁcation of the numbers of TRAPþ osteoclasts. C and D:
Similar experiments were performed in mice treated with Veh and ZOL. *P < 0.05, ***P < 0.001. Scale bar Z 100 mm (A and C).
Role of Osteoclasts in ONJthat there are statistically signiﬁcant differences in epithelial
wound closure (PZ 0.0009). However, in the BRONJ mouse
model (Figure 1B), there was no statistically different epithelial
wound closure (P Z 0.6392); 70% (7 of 10) of Veh-treated
mice and 60% (6 of 10) of ZOL-treated mice showed com-
plete epithelial closure (Figure 1D and Table 1).
mCT scans at the tooth-extracted sites revealed new bone
formation in the sockets as well as alveolar ridge resorption
around the sockets when there is complete wound closure in
both IgG- or anti-RANKL Ab-treated mice (Figure 1C). In
contrast, anti-RANKL Ab-treated mice without wound
closure exhibited unresorbed alveolar ridges and lack of
bone formation within the sockets (Figure 1C). Similar re-
sults were obtained in ZOL-treated groups (Figure 1D).
These data indicate that both anti-RANKL Ab and ZOL
cause a signiﬁcant delay in wound closure after tooth
extraction.
Further histological examination of these tooth-extracted
sites revealed that none of the control IgG-treated mice had
exposed bone; all mice had connective tissue directly above
the bone-ﬁlled sockets regardless of epithelial tissue closure
(Figure 2A). On the other hand, 50% of the anti-RANKLAb-
treated mice exhibited typical ONJ phenotypes, including the
following: i) breached oral mucosal tissues, ii) absence of
connective tissue layers, iii) denuded necrotic bone with
empty lacunae, and iv) pseudoepitheliomatous hyperplasia
invading onto the bone surfaces (Figure 2B). Unlike the
control groups, unresorbed sharp alveolar ridges wereThe American Journal of Pathology - ajp.amjpathol.orgprominently evident in anti-RANKL Ab-treated mice
(Figure 2B), suggesting that bone remodeling was inhibited.
The numbers of empty lacunae and the percentage of necrotic
bone were all signiﬁcantly higher in the anti-RANKL Ab-
treated mice that exhibited denuded bone compared with the
control group [7.68  1.80 versus 80.86  29.50
(P Z 0.013) for empty lacunae and 0.19  0.23 versus
13.16 4.69 (PZ 0.0087) for necrotic bone], indicating that
anti-RANKL Ab treatment causes ONJ-like lesions
(Figure 2, D and E). The remaining 50% of the anti-RANKL
Ab-treated mice were healed, as demonstrated by closed
epithelial and connective tissues (Figure 2C), exhibiting no
differences in the numbers of empty lacunae (5.20  1.88,
PZ 0.17) and the percentage of necrotic bone (2.18  1.50,
P Z 0.085) when compared with those from the control
group, suggesting that the anti-RANKL Ab-treated mice that
healed did not exhibit ONJ-like lesions. In the BRONJ
model, the similar patterns were observed (Figure 3, AeE)
[1.88  0.82 versus 11.06  5.55 (P < 0.047) for empty
lacunae and 0.69 0.47 versus 8.22  3.87 (PZ 0.029) for
necrotic bone].
Anti-RANKL Ab But Not ZOL Induces ONJ in the
Absence of TRAP-Positive Osteoclasts
To examine the presence of osteoclasts at the tooth-
extracted sites, we harvested the mice 2 weeks after
extraction, during which bone healing, including3089
Figure 5 Anti-RANKL Ab or zoledronate (ZOL) treatment diminishes
bone remodeling in vivo. Blood was collected from the control IgG- or anti-
RANKL Ab-treated mice 4 weeks after initial administration, and the serum
levels of TRAP 5b (A) or ALP (B) were evaluated using ELISAs. The serum
levels of TRAP 5b (C) and ALP (D) in mice treated with Veh or ZOL.
***P < 0.001.
Williams et alosteoclastic activity, is expected to be ongoing. Mature
osteoclasts positive to TRAP staining were identiﬁed and
were evident around the tooth-extracted sites in both
Veh- or IgG-treated mice (Figure 4, A and C). However,
all mice that received anti-RANKL Ab showed no TRAP-
positive osteoclasts regardless of ONJ development
(Figure 4, A and B). In sharp contrast, ZOL-treated mice
with ONJ-like lesions showed a similar degree of TRAP-
positive staining, if not slightly less, than those in the
control group (Figure 4, C and D), suggesting that
physical presence of osteoclasts is not associated with
ONJ development.Figure 6 Newly formed bone in the tooth-extracted sockets is inhibited
in osteonecrosis of the jaw (ONJ) lesions. Newly formed bone in the tooth-
extracted sockets was quantiﬁed using the micro computed tomography
scan from the DRONJ (A) or BRONJ (B) mouse model. ****P < 0.0001.TRAP and ALP Markers Are Systemically Diminished in
Both Anti-RANKL Ab- and ZOL-Treated Mice
To examine whether anti-RANKL Ab or ZOL suppressed
the bone remodeling process, including osteoclastic and
osteoblastic activity, we collected the blood samples and
measured the serum concentration of TRAP-5b and ALP,
biochemical markers for bone resorption and formation,
respectively.16 In anti-RANKL Ab-treated mice, TRAP-5b
in serum was notably suppressed to undetectable levels
(P < 0.0001) (Figure 5A). Similarly, TRAP-5b was also
decreased in ZOL-treated mice (P < 0.0001) (Figure 5C),
albeit to a lesser degree than those in anti-RANKL Ab-
treated mice. ALP was also decreased signiﬁcantly in both
antieRANKL-treated mice (P < 0.0001) (Figure 5B) and
ZOL-treated mice (P < 0.0001) (Figure 5D), indicating
bone remodeling in both antieRANKL- and ZOL-treated
mice is suppressed.3090Inhibition of New Bone Formation in the Tooth-
Extracted Sockets Is Associated with ONJ Lesions
Osteoclast-osteoblast coupling is an important bone
remodeling process at the bone surfaces during wound
healing.17 The fact that bone remodeling is suppressed in
both anti-RANKL Ab- and ZOL-treated mice suggests that
ONJ may be associated with bone formation in the tooth-
extracted socket. Indeed, our mCT scan images (Figure 1)
and histological sections (Figures 2 and 3) suggested that
lack of new bone formation within the extracted sockets is
associated with incomplete wound closure of the overlying
soft tissues and bone necrosis. To determine whether the
lack of new bone formation in the tooth-extracted socket is
associated with ONJ development, we quantiﬁed the newly
formed bone within the extracted socket using mCT anal-
ysis. In both BRONJ and DRONJ models, new bone for-
mation within the extracted sockets was signiﬁcantly
inhibited in an ONJ-speciﬁc manner (Figure 6), indicating
that lack of newly formed bone is associated with ONJ
lesions.
Discussion
Long-term use of BPs has been shown to increase the inci-
dence of developing ONJ after dental-related in-
terventions.1,18 Osteoclasts have been known for their key
roles in mediating ONJ because BPs improve bone density by
inhibiting bone resorption at the clinical level. However, a
direct link between inhibition of osteoclasts’ resorptive
functions and ONJ development as well as oral cavity
speciﬁcity is lacking, presumably due to the pleotropic ef-
fects of BPs. Dmab, another class of anti-resorptive drug, is a
fully human monoclonal Ab that speciﬁcally targets RANKL
and is known to induce ONJ.19 Herein, by developing a
mouse model for DRONJ and comparing it with BRONJ, we
found that the suppression of osteoclasts’ resorptive function
by these drugs is essential in inducing ONJ.
The primary role of mature osteoclasts is to resorb bone
matrix.20 However, roles other than bone resorption have
been suggested, such as modulating the differentiation of
nearby cells or secreting inﬂammatory cytokines to induceajp.amjpathol.org - The American Journal of Pathology
Role of Osteoclasts in ONJimmune responses.21 Indeed, recent studies suggest that
aberrant functions of osteoclasts may contribute to ONJ
development. In particular, Ephrin/Eph signaling plays an
important role in osteoclast-osteoblast interactions.22 It was
shown that alendronate enhances expression of ephrinB1 as
well as ephB1 and ephB3 in osteoclasts and osteoblasts,
respectively, to inhibit osteoblast differentiation, which may
explain the pathophysiological characteristics of ONJ.23 It
has also been postulated that isopentenyl diphosphate
released from BP-induced apoptotic osteoclasts at the bone
surface provokes oral innate immunity through gd T cells
and mediates a potential pathophysiological mechanism for
ONJ.6 These data support speculation that dysfunctional
osteoclasts affected by BPs (eg, osteoclasts undergoing BP-
mediated apoptosis) may play etiological roles in devel-
oping ONJ.
Interestingly, ONJ was developed in the absence of mature
osteoclasts in the DRONJ model (Figures 2 and 4A), which is
consistent with a recent ﬁnding,24 suggesting that the aber-
rant behaviors of BP-affected osteoclasts (eg, osteoclasts
undergoing apoptosis) may not be associated with ONJ
development. Rather, unresorbed bone surfaces due to
impaired osteoclast functions or formation by BPs or Dmab
are directly associated with ONJ development.
In the BRONJ mouse model, histological examination
revealed that only 30% of mice treated with ZOL developed
ONJ-like lesions (Figure 5A). The incidence of ONJ
development by BP in other animal models ranges from
15% to 50%, depending on the method, duration, and
amount of drugs delivered.6,17 For mouse models in
particular, the incidence of ONJ development when treated
with BP was 20% to 30%,5,15 which is similar to the inci-
dence we obtained (Table 1).
In contrast, incidence of ONJ lesions in anti-RANKL Ab-
treated mice was higher than that in ZOL-treated mice (50%
versus 30%) (Table 1). Such difference is, in part, due to the
fact that osteoclastogenesis was completely abolished in the
DRONJ model, whereas it was only partially suppressed in
the BRONJ model (Figures 4, A and B, and 5A).
Compared with our animal models, previous clinical
studies reveal minimal differences between the incidence of
ONJ by BPs and Dmab (1.3% versus 1.5%, respectively).3,4
Dmab was recently introduced in 2011 for clinical use, and
clinical studies about ONJ development in Dmab users are
still accumulating. Nonetheless, recent studies suggest that
ONJ may occur in a relatively shorter period of time, even
within a year, in Dmab users.25e27 Because Dmab is known
to be more potent than BP in inhibiting resorptive function
of osteoclasts, the onset of ONJ by Dmab may require
careful monitoring in the clinic.
Surprisingly, complete inhibition of osteoclastogenesis by
anti-RANKL Ab treatment did not induce ONJ in all mice.
Despite complete absence of mature osteoclasts at the tooth-
extracted sites (Figure 4, A and B), 50% of the anti-RANKL
Ab-treated mice were healed. Such observation implies that,
although required, the lack of osteoclast’s resorptiveThe American Journal of Pathology - ajp.amjpathol.orgfunction mediated by BPs and Dmab is not sufﬁcient to
induce ONJ. Further parallel comparisons between the
clinical presentations and mCT scanning images of tooth-
extracted sites in both BRONJ and DRONJ mice models
revealed a striking correlation between new bone formation
within the sockets and complete wound closure of oral
mucosa (Figures 2, 3, and 6), suggesting that newly formed
bone (alias woven bone) may play a key role during the
healing process in the oral cavity.
Woven bone formation is known to occur in two ways:
appositional formation from the existing bone surfaces pri-
marily mediated by the osteoclast-osteoblast coupling
mechanism, and de novo formation without any existing
bone surfaces.28 This dual mode of new bone formation is
known to play an important role during healing in the oral
cavity after dental interventions, such as implant surgery.29
In the context of wound healing after tooth extraction,
appositional bone formation mandates tight coupling be-
tween initial bone resorption mediated by mature osteoclasts
and subsequent bone formation by recruiting osteoblasts at
the resorbed sites.17 As such, a defect in this coupling
process due to impaired osteoclasts’ resorptive function in
the presence of BP and Dmab may interfere and inhibit
appositional woven bone formation, leaving de novo bone
formation as the only source of new bone formation in the
extracted sockets. Consistent with this notion, a closer ex-
amination reveals a clear demarcation at the interface be-
tween the existing bone and newly formed bone (Figures 2C
and 3C), suggesting that woven bone formation during
healing after extraction in the presence of anti-resorptive
agents was primarily mediated by de novo bone formation.
The oral cavity is a unique entity because bone is situated
immediately beneath the oral mucosal tissues and there are
no remarkable anatomical structures (eg, fascia, muscle, and
fat) between these soft and hard tissues. For this anatomical
reason, healing of the soft and hard tissues, so-called
osteomucosal healing, usually occurs simultaneously in
the oral cavity after trauma (eg, tooth extraction). Indeed,
early stages of woven bone formation at healing sites
require deposition of collagens onto which mineralization
occurs.30 Collagens are integral parts of extracellular ma-
trixes not only for bone formation but also for connective
tissue formation onto which epithelial cells migrate to close
the wounded sites. Therefore, it is tempting to speculate that
woven bone formation plays a critical role in the osteomu-
cosal healing process by physically bridging soft and hard
tissues in the oral cavity.
Recent studies suggest that bacterial infection and in-
ﬂammatory responses may play an integral part of the ONJ
pathophysiological characteristics because bacterial coloni-
zation in the ONJ lesions is inevitably always present both
at the clinical level and animal models.8,30e33 Therefore, it
is also possible that inability to remove bacteria-infected
bone by osteoclasts impairs the body’s ability to resolve
the infected bone, ultimately leading to bone death. As such,
the absence of woven bone may be a result, rather than a3091
Williams et alcause, of osteonecrosis. The precise role of woven bone
formation at or near the bacteria-infected bone warrants
closer examination.
Although we put our efforts to compare ONJ induced by
BP and anti-RANKL Ab, there are several limitations to
such direct comparison. First, we used only a single dose of
each drug (eg, 250 mg of anti-mouse RANKL monoclonal
Ab or 125 mg/kg of ZOL). Second, effects of anti-RANKL
Ab are rapid, whereas those of ZOL are relatively slow as it
accumulates in bone. Inevitably, these dose and duration
effects of anti-resorptive agents are also challenging to
standardize in the clinical settings. As such, careful inter-
pretation should be considered when comparing ONJ inci-
dence by BPs and Dmab.
In conclusion, we have developed a mouse model for
DRONJ and compared it with the BRONJ mouse model to
test our hypothesis that inhibition of bone resorption by
osteoclasts plays a direct etiological role in inducing ONJ by
these anti-resorptive agents, BP and Dmab. We also showed
that woven bone formation in the extracted sockets is
associated with ONJ lesions. Many BP and Dmab users
taking high doses are in life-threatening conditions with
metastatic bone cancer. Therefore, further examination is
necessary as to whether therapeutic modalities that enhance
woven bone formation in the absence of osteoclasts’ bone-
resorptive functions by BP and Dmab may provide means to
intervene and prevent ONJ development.Acknowledgment
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